BWCS
BMRN icon

Beirne Wealth Consulting Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Beirne Wealth Consulting Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,819
Closed -$247K – 121
2020
Q4 		$247K Buy
+2,819
New +$223K 0.12% 126

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Beirne Wealth Consulting Services's BMRN Position: Q1 2021 in Review

Beirne Wealth Consulting Services sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 2,819 shares — an estimated $247K sold.

Beirne Wealth Consulting Services first reported a position in BMRN in Q4 2020 and held it in 1 quarter. The position peaked at $247K in Q4 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • Beirne Wealth Consulting Services reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Beirne Wealth Consulting Services sold 2,819 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $247K.
  • Beirne Wealth Consulting Services first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Beirne Wealth Consulting Services's BioMarin Pharmaceuticals position peaked at $247K in Q4 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Beirne Wealth Consulting Services's 13F filing for Q1 2021, filed 17 May 2021.